Really looking forward to this year’s #ESCcongress in Barcelona 📍 and to reunite with friends and colleagues - it’s been quite some time 🦠

An analysis of Danish registry data show that #NSAID use, even for a short time, could raise risk for new-onset HF hospitalization among adults with type 2 diabetes Copenhagen Cardiovascular Research Center Anders Holt #CardioTwitter #ESCCongress Endocrine Today healio.com/news/cardiolog…

Ischemic evaluation and revascularization in patients with new-onset heart failure - will REVIVED change our clinical practice? sciencedirect.com/science/articl…

Live from HerlevGentofte Hosp. #ResearchSymposium22 📍🏥Caroline Hartwell Garred presenting her recently published study on adherence to HF therapies acc to age🥇Herlev og Gentofte hosp afd for hjertesygdomme Copenhagen Cardiovascular Research Center

Dinner with the most inspiring colleagues 🌟 Copenhagen Cardiovascular Research Center ❤️

Room for improvement? Fundamental heart failure treatments are markedly underused in primary care. Access the hot off the press paper: doi.org/10.1002/ehf2.1… Mikael Kjær Poulsen Per Warrer Petersen Bo Gerdes Kasper Rossing morten schou Copenhagen Cardiovascular Research Center

New insights from PARAGON-HF on the relationship between red cell distribution width and clinical outcomes in patients with HFpEF 🫀brilliantly presented by Dr. Jawad Haider Butt MD as always #ACC2023 #ACC #HFpEF #PARAGON

A 25-year perspective of age-specific trends in mortality rate in patients with heart failure presented by the talented Dr. Caroline Hartwell Garred 📊 #ACC23 #HeartFailure

Heading home to 🇩🇰 from this years #ACC #WCC. What an experience!

A poem by prof. Thomas Gerds (and #ChatGPT) on why you should always include a statistician in planning an RCT 🎯 Copenhagen Cardiovascular Research Center #CardioTwitter Thomas Alexander Gerds🥇

In this The Lancet sdy Mariam Elmegaard et al found that in 77,745 ptts w first time SGLT2-is and 56,037 GLP1-RAs the risk of discontinuing was 56% and 45%, respectively, w a decreased risk over the sdy-period thelancet.com/journals/lanep… #Cardiotwitter @cardiology @diabetes

Data on all Danish first-time users of SGLT2is and GLP1-RAs from 2013 to 2021 show that ~50% discontinued therapy within five years, but a quarter of these reinitiated therapy during the following year. Discontinuation rates decreasing with time. thelancet.com/journals/lanep…

Nationwide, case-crossover study of >330k pts w/ #diabetes found assoc between short-term #NSAID use and risk of #HF, strongest assoc in age >79 & elevated HbA1c. Results could help physicians mitigate risk if prescribing NSAIDs for diabetes pts. bit.ly/3KutBhj #JACC

In this JACC Journals sdy of >330,000 pts w DM Anders Holt et al found asso between short-term NSAID use and ⬆️ w solid fill risk of HF, strongest asso in age >79 and elevated HbA1c. 😊 bit.ly/43pNbE4 #CardioTwitter

Just out in European Heart Journal European Society of Cardiology Journals: 2001-2019 - CHD💔patients faced ⬆️ rates of #OHCA🧎🏻cmprd w cntrls across severities🧮. But equal 30d survival due to pre-hospital chain academic.oup.com/eurheartj/adva… #ACHD #CVD #cardiotwitter #escardio Copenhagen Cardiovascular Research Center EHJ Editor-in-Chief Carlo Alberto Barcella

It can be difficult to discern high quality observational studies from the rest. But it is critical that we try. Sharing some of the things I've learned here: Bringing the Credibility Revolution to Observational Research in Cardiology | Circulation ahajournals.org/doi/10.1161/CI…

👏Mariam Elmegaard presented her impressive study in light of the new ESC 2023 guidelines for the management of CVD in T2D. Should we focus more on preventing cardiorenal disease in patients without established CVD and CKD 🤔? #ESCCongress Dansk Cardiologisk Selskab (DCS) #DCS_ESC23 morten schou

In this cross-sectional nationwide The Lancet Healthy Longevity study Mariam Elmegaard and morten schou et al showed #frailty was associated with a ⬇️lower probability of SGLT2-inhibitor or GLP-1 receptor-agonist initiation, despite their benefits Free 🔗 thelancet.com/journals/lanhl…

Selvom ældre og skrøbelige patienter kan have særlig god gavn af behandling med SGLT2-hæmmere og GLP-1-receptoragonister for type-2 diabetes, hjertekarsygdom og nyresygdom, bliver de alt for sjældent startet op i behandlingerne #sundpol buff.ly/3PSa1j4

New: Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study by Mariam Elmegaard and colleagues thelancet.com/journals/lanhl…